OMEROS CORP
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
OMER$17.30-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating activities: | |||
| Net income (loss) | $(117,813) | $47,417 | $194,235 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||
| Stock-based compensation expense | 11,650 | 14,072 | 17,630 |
| Non-cash interest expense on convertible senior notes | 1,853 | 1,830 | 1,696 |
| Depreciation and amortization | 920 | 952 | 1,386 |
| Remeasurement on OMIDRIA contract royalty asset | (41,167) | (14,457) | — |
| Interest on OMIDRIA contract royalty asset | (15,315) | (18,634) | — |
| Accretion on U.S. government treasury bills, net | (8,714) | — | — |
| Gain on early extinguishment of convertible senior notes | (4,112) | — | — |
| Gain on sale of OMIDRIA, gross | — | — | (310,563) |
| Non-cash interest expense on future royalty obligation | — | 1,695 | — |
| Changes in operating assets and liabilities: | |||
| Receivables | 205,125 | (175,066) | (34,314) |
| OMIDRIA contract royalty asset | 40,595 | 65,439 | — |
| Accounts payable and accrued expense | 4,682 | (10,665) | 14,640 |
| Prepaid expenses and other | (2,978) | 934 | 5,568 |
| Net cash provided by (used in) operating activities | 74,726 | (86,483) | (109,722) |
| Investing activities: | |||
| Purchases of investments | (1,018,602) | (429,045) | (32,006) |
| Proceeds from the sale and maturities of investments | 1,046,482 | 301,594 | 100,000 |
| Purchases of property and equipment | (426) | (113) | (277) |
| Cash proceeds on sale of OMIDRIA | — | — | 125,993 |
| Net cash provided by (used in) investing activities | 27,454 | (127,564) | 193,710 |
| Financing activities: | |||
| Payments on convertible senior notes | (99,873) | — | — |
| Repurchases on common stock | (4,654) | — | — |
| Principal payments on OMIDRIA royalty obligation | (1,152) | (417) | — |
| Payments on finance lease obligations | (555) | (750) | (1,823) |
| Proceeds upon exercise of stock options | 150 | 415 | 8,383 |
| Proceeds upon entering into OMIDRIA royalty obligation | — | 125,000 | — |
| At the market offering costs | — | — | (241) |
| Net cash provided by (used in) financing activities | (106,084) | 124,248 | 6,319 |
| Net increase (decrease) in cash and cash equivalents | (3,904) | (89,799) | 90,307 |
| Cash and cash equivalents at beginning of period | 11,009 | 100,808 | 10,501 |
| Cash and cash equivalents at end of period | $7,105 | $11,009 | $100,808 |
| Supplemental cash flow information | |||
| Cash paid for interest | $29,923 | $19,178 | $17,876 |
| Equipment acquired under finance lease | $952 | $40 | $289 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.